RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Clinical trials for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GLIOBLASTOMA, IDH-WILDTYPE trials appear
Sign up with your email to follow new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive antibody and immunotherapy combo targets recurrent brain cancer
Disease control Not yet recruitingThis early-phase trial tests a new combination for recurrent glioblastoma, a fast-growing brain tumor. The treatment pairs Actimab-A, a radioactive antibody that seeks out cancer cells, with cemiplimab, an immunotherapy that helps the immune system attack tumors. About 30 adults …
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New brain cancer wafer shows promise in recurrent glioblastoma trial
Disease control Not yet recruitingThis study tests a new treatment called Cerebraca Wafer for people with recurrent glioblastoma, a serious brain cancer. The wafer is placed in the brain during surgery and is followed by standard chemotherapy. The goal is to see if it helps people live longer and controls the dis…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE2, PHASE3 • Sponsor: Everfront Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC